Fizazi, et al. ARAMIS: Efficacy and safety of darolutamide in nonmetastatic castration-resistant prostate cancer (nmCRPC). ASCO-GU 2019, abstract 140.
Vaak specifieke DNA-afwijkingen bij atypische tumoren Lynch-syndroom
apr 2023 | Gynaecologische oncologie, Immuuntherapie, Maag-darm-leveroncologie